By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Vertex Pharmaceuticals Incorporated 

Corporate Headquarters
130 Waverly Street
Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced

Key Statistics

Ownership: Public

Web Site: Vertex
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

Company News
Vertex (VRTX) To Present At The Piper Jaffray Healthcare Conference On December 1 11/24/2015 9:21:27 AM
Vertex (VRTX) Appoints Michael J. Parini As Executive Vice President And Chief Legal Officer 11/23/2015 10:11:10 AM
Seres Therapeutics Signs Huge Lease at Vertex (VRTX)'s Former Digs in Massachusetts 11/23/2015 10:07:44 AM
Vertex (VRTX) Receives EU Approval For ORKAMBI (Lumacaftor/Ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People Ages 12 And Older With Two Copies Of The F508del Mutation 11/20/2015 11:28:39 AM
Vertex (VRTX) Receives Two EU Approvals For KALYDECO (ivacaftor) For People With Cystic Fibrosis 11/18/2015 11:13:49 AM
How Vertex (VRTX)'s Long-Term $500K Gamble Paid Off with a $30 Billion Return 11/17/2015 6:33:12 AM
Vertex (VRTX) To Present At The Credit Suisse Healthcare Conference On November 10 11/5/2015 11:36:39 AM
Vertex (VRTX)’s Profitability Hints It May Be Shopping Soon 11/4/2015 6:22:19 AM
Feds Subpoena Vertex (VRTX) Documents Regarding Laboratory Practices 11/2/2015 6:42:24 AM
Vertex (VRTX) Reports Third Quarter 2015 Financial Results 10/29/2015 11:05:01 AM